POP Biotechnologies
POP Biotechnologies is dedicated to advancing medical breakthroughs through innovative nanotechnology solutions, focusing on oncology and infectious disease. Their proprietary SNAP technology enables rapid vaccine development and targeted therapies, aiming to transform treatment approaches in these critical areas.
POP Biotechnologies
1576 Sweet Home Road, Suite 221, Buffalo, NY 14228
What We Do
Nanomedicine Development
Development of nanomedicines using patented porphyrin-phospholipid (PoP) liposome technologies to address needs in infectious disease and oncology.
Accelerated Vaccine Development
Utilizing the SNAP platform for the rapid development of highly immunogenic vaccines.
Targeted Chemotherapy
Chemophototherapy (CPT) using PoP liposomes to deliver targeted concentrations of chemotherapy drugs to tumors exposed to specific laser light.
EuCorVac-19
A protein-based vaccine targeting SARS-CoV-2, currently in Phase 3 clinical trials.
SNAPflu
A hexavalent seasonal influenza vaccine developed using SNAP technology for broader coverage and lasting immunity.
PhotoDOX
A light-activated chemotherapy approach designed to treat solid tumors with minimal systemic toxicity.
Vaccines
Show LessInfectious Diseases
Key People
Dr. Baik YoungOk
CEO of EuBiologics
Mr. Seukkeun Choi
Executive at EuBiologics
News & Updates
Positive results for a pentavalent peptide vaccine targeting Alzheimer’s Disease, demonstrating efficacy in mice and advancing toward clinical trials.
Collaboration with FunPep for advanced preclinical testing of antibody-inducing peptides.
Commencement of dosing for the shingles vaccine 'EuHZV' in collaboration with EuBiologics in a Phase 1 clinical study in Korea.
Patent for formulations that enhance immunization targeting MHC-I restricted epitopes.
Patent for formulations targeting the receptor binding domain of SARS-CoV-2.
Patent for nanostructures that enhance drug delivery and targeting.